These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35276361)

  • 1. WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
    Bhawsar S; Joshi S; Deshpande P; Yeole R; Bhagwat S; Patel M
    Bioorg Med Chem Lett; 2022 May; 63():128665. PubMed ID: 35276361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes.
    Al-Lahham A; De Souza NJ; Patel M; René Reinert R
    J Antimicrob Chemother; 2005 Dec; 56(6):1130-3. PubMed ID: 16239291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the new quinolone WCK 771 against staphylococci.
    Jacobs MR; Bajaksouzian S; Windau A; Appelbaum PC; Patel MV; Gupte SV; Bhagwat SS; De Souza NJ; Khorakiwala HF
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3338-42. PubMed ID: 15328094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the new quinolone WCK 771 against pneumococci.
    Appelbaum PC; Pankuch GA; Bozdogan B; Lin G; Jacobs MR; Patel MV; Gupte SV; Jafri MA; De Souza NJ; Khorakiwala HF
    Clin Microbiol Infect; 2005 Jan; 11(1):9-14. PubMed ID: 15649298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection.
    Bhawsar S; Kale R; Deshpande P; Yeole R; Bhagwat S; Patel M
    Bioorg Med Chem Lett; 2021 Dec; 54():128432. PubMed ID: 34757217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
    J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WCK 4034: A promising oxazolidinone for treating gram positive infections.
    Bhawsar S; Pawar S; Deshpande P; Yeole R; Chavan R; Nandanwar M; Bhagwat S; Patel M
    Bioorg Med Chem Lett; 2022 Sep; 71():128842. PubMed ID: 35680102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
    Patel SN; McGeer A; Melano R; Tyrrell GJ; Green K; Pillai DR; Low DE;
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3703-8. PubMed ID: 21628545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.
    Tellis M; Joseph J; Khande H; Bhagwat S; Patel M
    J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin Derivatives with Potential Antibacterial Activity against Methicillin- Resistant Staphylococcus Aureus (MRSA).
    Chen R; Xue H; Xu Y; Ma T; Liu Y; Zhang J; Shi X; Guo D
    Curr Top Med Chem; 2021; 21(27):2474-2482. PubMed ID: 34645377
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
    Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA.
    Saxena D; Kaul G; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].
    Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV
    Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.